We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
There have been reports of rejection of solid organ transplants in patients treated with nivolumab or pembrolizumab. Ipilimumab (Yervoy▼) may also interfere with immunosuppressive therapy, increasing the risk of graft rejection.
MSD successfully put their advanced new melanoma treatment through MHRA's early access to medicine scheme (EAMS).
Patients with advanced melanoma are among the first in the world to access pembrolizumab through the early access to medicines scheme (EAMS).
As with any medicine, the MHRA will keep the safety and effectiveness of sevabertinib under close review.
As with all products, we will keep its safety under close review
As with all products, the MHRA will keep its safety under close review.
List of currently authorised veterinary medicines containing controlled drugs (CDs) and their requirements for special storage and witnessed destruction.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab and requires JavaScript).